JHS Svendgaard Laboratories Ltd
Incorporated in 1997, JHS Svendgaard Laboratories Ltd does manufacturing of
oral and dental products for national and international brands[1]
- Market Cap ₹ 75.2 Cr.
- Current Price ₹ 8.47
- High / Low ₹ 13.9 / 6.15
- Stock P/E
- Book Value ₹ 20.0
- Dividend Yield 0.00 %
- ROCE -0.77 %
- ROE -1.10 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 0.42 times its book value
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 0.96% over past five years.
- Promoter holding is low: 33.8%
- Company has a low return on equity of -4.74% over last 3 years.
- Earnings include an other income of Rs.2.55 Cr.
- Promoter holding has decreased over last 3 years: -8.38%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 55 | 100 | 104 | 138 | 120 | 133 | 97 | 80 | 85 | 71 | 92 | 102 | 109 | |
| 59 | 93 | 92 | 122 | 111 | 123 | 93 | 80 | 94 | 72 | 96 | 99 | 106 | |
| Operating Profit | -4 | 7 | 12 | 17 | 8 | 9 | 4 | 0 | -9 | -1 | -4 | 3 | 3 |
| OPM % | -7% | 7% | 11% | 12% | 7% | 7% | 3.8% | 0.2% | -11% | -1.3% | -4.3% | 2.6% | 2.8% |
| -6 | -17 | 0 | 32 | 5 | 1 | 6 | 8 | -7 | 4 | 0 | 3 | 3 | |
| Interest | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 1 |
| Depreciation | 12 | 10 | 6 | 7 | 7 | 7 | 6 | 6 | 6 | 6 | 8 | 8 | 7 |
| Profit before tax | -22 | -22 | 5 | 41 | 5 | 2 | 3 | 2 | -23 | -3 | -12 | -2 | -3 |
| Tax % | 0% | 0% | -326% | 32% | 31% | 1% | 13% | 228% | -24% | 18% | 58% | -16% | |
| -22 | -22 | 22 | 28 | 4 | 2 | 3 | -2 | -18 | -4 | -20 | -2 | -2 | |
| EPS in Rs | -9.19 | -5.75 | 4.98 | 4.61 | 0.59 | 0.29 | 0.43 | -0.38 | -2.70 | -0.52 | -2.31 | -0.22 | -0.22 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 1% |
| 3 Years: | 6% |
| TTM: | 19% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 88% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -13% |
| 5 Years: | -19% |
| 3 Years: | -26% |
| 1 Year: | -23% |
| Return on Equity | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | -3% |
| 3 Years: | -5% |
| Last Year: | -1% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 24 | 38 | 44 | 61 | 61 | 61 | 64 | 65 | 78 | 78 | 86 | 87 |
| Reserves | 78 | 63 | 91 | 116 | 119 | 121 | 127 | 125 | 96 | 92 | 88 | 88 |
| 19 | 2 | 2 | 2 | 7 | 3 | 2 | 2 | 3 | 5 | 6 | 15 | |
| 33 | 19 | 19 | 26 | 33 | 46 | 21 | 19 | 39 | 22 | 25 | 26 | |
| Total Liabilities | 153 | 123 | 156 | 205 | 220 | 230 | 215 | 211 | 215 | 197 | 204 | 216 |
| 108 | 65 | 65 | 71 | 69 | 58 | 59 | 55 | 65 | 90 | 90 | 89 | |
| CWIP | 0 | 1 | 1 | 0 | 5 | 7 | 9 | 16 | 9 | 1 | 0 | 4 |
| Investments | 0 | 0 | 1 | 18 | 15 | 17 | 14 | 15 | 3 | 3 | 4 | 5 |
| 46 | 57 | 89 | 116 | 130 | 148 | 133 | 125 | 139 | 103 | 110 | 117 | |
| Total Assets | 153 | 123 | 156 | 205 | 220 | 230 | 215 | 211 | 215 | 197 | 204 | 216 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7 | -6 | -4 | 13 | -10 | 15 | 15 | -11 | 23 | -9 | -5 | -3 | |
| 1 | 4 | -3 | -27 | 1 | -7 | -6 | -1 | 10 | -22 | -20 | -12 | |
| -10 | 4 | 10 | 14 | 4 | -8 | 6 | 0 | -1 | 2 | 23 | 11 | |
| Net Cash Flow | -1 | 2 | 3 | 0 | -5 | -0 | 16 | -12 | 32 | -28 | -2 | -3 |
| Free Cash Flow | 8 | -7 | -17 | 3 | -13 | 7 | 7 | -14 | 21 | -33 | -14 | -15 |
| CFO/OP | -181% | -91% | -33% | 96% | -115% | 158% | 436% | -6,094% | -256% | 949% | 117% | -77% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 82 | 25 | 48 | 113 | 171 | 262 | 221 | 74 | 80 | 66 | 52 | 60 |
| Inventory Days | 94 | 53 | 96 | 59 | 51 | 19 | 76 | 104 | 128 | 176 | 153 | 85 |
| Days Payable | 106 | 67 | 125 | 123 | 134 | 179 | 126 | 147 | 221 | 197 | 141 | 100 |
| Cash Conversion Cycle | 70 | 12 | 19 | 48 | 88 | 101 | 171 | 31 | -13 | 46 | 63 | 45 |
| Working Capital Days | -158 | 58 | 48 | 128 | 168 | 188 | 246 | 287 | 42 | 51 | 48 | 42 |
| ROCE % | -14% | -3% | 5% | 9% | 4% | 7% | 2% | 1% | -2% | -2% | -5% | -1% |
Insights
In beta| Mar 2017 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| Export revenue share % of revenue |
|
|||||||
| Toothbrush revenue share % of revenue |
||||||||
| Toothpaste revenue share % of revenue |
||||||||
| Number of permanent employees count |
||||||||
| Talcum and other new categories revenue share % of revenue |
||||||||
Extracted by Screener AI
Documents
Announcements
- Closure of Trading Window
-
Letter To Shareholders
- Annual report shared; 22nd AGM on 26 September 2026, with e-voting from 23-25 September.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Newspaper Publication regarding dispatch of 22nd AGM Notice
-
Notice Of 22Nd Annual General Meeting
- 22nd AGM on September 26, 2026 at 3:00 PM via VC/OAVM; Paramvir Singh seeks reappointment.
-
Reg. 34 (1) Annual Report.
- Integrated Annual Report FY2025-26 and notice for 22nd AGM uploaded.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
Concalls
-
May 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Jun 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022PPT
-
Jun 2022Transcript PPT
-
Feb 2022PPT
-
Nov 2021PPT
-
Aug 2021PPT
History
The company is currently a contract manufacturer and does earned any revenue from Aquawhite, Dr. Gold, or any owned brand. The retail business was demerged into JHS Svendgaard Retail Ventures Ltd under a scheme effective Aug,23, while JHS Svendgaard Brands Ltd was amalgamated into JHS.[1] [2]
A proposed amalgamation with Vedic Cosmeceuticals Pvt Ltd was withdrawn in FY24 because of integration and practical issues.[3]